Evaluation of Anti-Activated Factor X Activity and Activated Partial Thromboplastin Time Relations and Their Association with Bleeding and Thrombosis during Veno-Arterial ECMO Support: A Retrospective Study. Moussa, M. D., Soquet, J., Lamer, A., Labreuche, J., Gantois, G., Dupont, A., Abou-Arab, O., Rousse, N., Liu, V., Brandt, C., Foulon, V., Leroy, G., Schurtz, G., Jeanpierre, E., Duhamel, A., Susen, S., Vincentelli, A., & Robin, E. Journal of Clinical Medicine, 10(10):2158, January, 2021. Number: 10 Publisher: Multidisciplinary Digital Publishing Institute![Evaluation of Anti-Activated Factor X Activity and Activated Partial Thromboplastin Time Relations and Their Association with Bleeding and Thrombosis during Veno-Arterial ECMO Support: A Retrospective Study [link]](https://bibbase.org/img/filetypes/link.svg "link")
Paper doi abstract bibtex Background: We aimed to investigate the relationship between anti-activated Factor X (anti-FXa) and activated Partial Thromboplastin Time (aPTT), and its modulation by other haemostasis co-variables during veno-arterial extracorporeal membrane oxygenation (VA-ECMO) support. We further investigated their association with serious bleeding and thrombotic complications. Methods: This retrospective single-center study included 265 adults supported by VA-ECMO for refractory cardiogenic shock from January 2015 to June 2019. The concordance of anti-FXa and aPTT and their correlations were assessed in 1699 paired samples. Their independent associations with serious bleeding or thrombotic complications were also analysed in multivariate analysis. Results: The concordance rate of aPTT with anti-FXa values was 50.7%, with 39.3% subtherapeutic aPTT values. However, anti-FXa and aPTT remained associated (β = 0.43 (95% CI 0.4–0.45) 10−2 IU/mL, p < 0.001), with a significant modulation by several biological co-variables. There was no association between anti-FXa nor aPTT values with serious bleeding or with thrombotic complications. Conclusion: During VA-ECMO, although anti-FXa and aPTT were significantly associated, their values were highly discordant with marked sub-therapeutic aPTT values. These results should favour the use of anti-FXa. The effect of biological co-variables and the failure of anti-FXa and aPTT to predict bleeding and thrombotic complications underline the complexity of VA-ECMO-related coagulopathy.
@article{moussa_evaluation_2021,
title = {Evaluation of {Anti}-{Activated} {Factor} {X} {Activity} and {Activated} {Partial} {Thromboplastin} {Time} {Relations} and {Their} {Association} with {Bleeding} and {Thrombosis} during {Veno}-{Arterial} {ECMO} {Support}: {A} {Retrospective} {Study}},
volume = {10},
copyright = {http://creativecommons.org/licenses/by/3.0/},
shorttitle = {Evaluation of {Anti}-{Activated} {Factor} {X} {Activity} and {Activated} {Partial} {Thromboplastin} {Time} {Relations} and {Their} {Association} with {Bleeding} and {Thrombosis} during {Veno}-{Arterial} {ECMO} {Support}},
url = {https://www.mdpi.com/2077-0383/10/10/2158},
doi = {10.3390/jcm10102158},
abstract = {Background: We aimed to investigate the relationship between anti-activated Factor X (anti-FXa) and activated Partial Thromboplastin Time (aPTT), and its modulation by other haemostasis co-variables during veno-arterial extracorporeal membrane oxygenation (VA-ECMO) support. We further investigated their association with serious bleeding and thrombotic complications. Methods: This retrospective single-center study included 265 adults supported by VA-ECMO for refractory cardiogenic shock from January 2015 to June 2019. The concordance of anti-FXa and aPTT and their correlations were assessed in 1699 paired samples. Their independent associations with serious bleeding or thrombotic complications were also analysed in multivariate analysis. Results: The concordance rate of aPTT with anti-FXa values was 50.7\%, with 39.3\% subtherapeutic aPTT values. However, anti-FXa and aPTT remained associated (β = 0.43 (95\% CI 0.4–0.45) 10−2 IU/mL, p \< 0.001), with a significant modulation by several biological co-variables. There was no association between anti-FXa nor aPTT values with serious bleeding or with thrombotic complications. Conclusion: During VA-ECMO, although anti-FXa and aPTT were significantly associated, their values were highly discordant with marked sub-therapeutic aPTT values. These results should favour the use of anti-FXa. The effect of biological co-variables and the failure of anti-FXa and aPTT to predict bleeding and thrombotic complications underline the complexity of VA-ECMO-related coagulopathy.},
language = {en},
number = {10},
urldate = {2021-05-17},
journal = {Journal of Clinical Medicine},
author = {Moussa, Mouhamed Djahoum and Soquet, Jérôme and Lamer, Antoine and Labreuche, Julien and Gantois, Guillaume and Dupont, Annabelle and Abou-Arab, Osama and Rousse, Natacha and Liu, Vincent and Brandt, Caroline and Foulon, Valentin and Leroy, Guillaume and Schurtz, Guillaume and Jeanpierre, Emmanuel and Duhamel, Alain and Susen, Sophie and Vincentelli, André and Robin, Emmanuel},
month = jan,
year = {2021},
note = {Number: 10
Publisher: Multidisciplinary Digital Publishing Institute},
keywords = {activated partial thromboplastin time, anti-factor Xa, bleeding, extracorporeal membrane oxygenation, intravenous unfractionated heparin monitoring, thrombotic complications},
pages = {2158},
}
Downloads: 0
{"_id":"xrXftQsnroexqZko9","bibbaseid":"moussa-soquet-lamer-labreuche-gantois-dupont-abouarab-rousse-etal-evaluationofantiactivatedfactorxactivityandactivatedpartialthromboplastintimerelationsandtheirassociationwithbleedingandthrombosisduringvenoarterialecmosupportaretrospectivestudy-2021","author_short":["Moussa, M. D.","Soquet, J.","Lamer, A.","Labreuche, J.","Gantois, G.","Dupont, A.","Abou-Arab, O.","Rousse, N.","Liu, V.","Brandt, C.","Foulon, V.","Leroy, G.","Schurtz, G.","Jeanpierre, E.","Duhamel, A.","Susen, S.","Vincentelli, A.","Robin, E."],"bibdata":{"bibtype":"article","type":"article","title":"Evaluation of Anti-Activated Factor X Activity and Activated Partial Thromboplastin Time Relations and Their Association with Bleeding and Thrombosis during Veno-Arterial ECMO Support: A Retrospective Study","volume":"10","copyright":"http://creativecommons.org/licenses/by/3.0/","shorttitle":"Evaluation of Anti-Activated Factor X Activity and Activated Partial Thromboplastin Time Relations and Their Association with Bleeding and Thrombosis during Veno-Arterial ECMO Support","url":"https://www.mdpi.com/2077-0383/10/10/2158","doi":"10.3390/jcm10102158","abstract":"Background: We aimed to investigate the relationship between anti-activated Factor X (anti-FXa) and activated Partial Thromboplastin Time (aPTT), and its modulation by other haemostasis co-variables during veno-arterial extracorporeal membrane oxygenation (VA-ECMO) support. We further investigated their association with serious bleeding and thrombotic complications. Methods: This retrospective single-center study included 265 adults supported by VA-ECMO for refractory cardiogenic shock from January 2015 to June 2019. The concordance of anti-FXa and aPTT and their correlations were assessed in 1699 paired samples. Their independent associations with serious bleeding or thrombotic complications were also analysed in multivariate analysis. Results: The concordance rate of aPTT with anti-FXa values was 50.7%, with 39.3% subtherapeutic aPTT values. However, anti-FXa and aPTT remained associated (β = 0.43 (95% CI 0.4–0.45) 10−2 IU/mL, p < 0.001), with a significant modulation by several biological co-variables. There was no association between anti-FXa nor aPTT values with serious bleeding or with thrombotic complications. Conclusion: During VA-ECMO, although anti-FXa and aPTT were significantly associated, their values were highly discordant with marked sub-therapeutic aPTT values. These results should favour the use of anti-FXa. The effect of biological co-variables and the failure of anti-FXa and aPTT to predict bleeding and thrombotic complications underline the complexity of VA-ECMO-related coagulopathy.","language":"en","number":"10","urldate":"2021-05-17","journal":"Journal of Clinical Medicine","author":[{"propositions":[],"lastnames":["Moussa"],"firstnames":["Mouhamed","Djahoum"],"suffixes":[]},{"propositions":[],"lastnames":["Soquet"],"firstnames":["Jérôme"],"suffixes":[]},{"propositions":[],"lastnames":["Lamer"],"firstnames":["Antoine"],"suffixes":[]},{"propositions":[],"lastnames":["Labreuche"],"firstnames":["Julien"],"suffixes":[]},{"propositions":[],"lastnames":["Gantois"],"firstnames":["Guillaume"],"suffixes":[]},{"propositions":[],"lastnames":["Dupont"],"firstnames":["Annabelle"],"suffixes":[]},{"propositions":[],"lastnames":["Abou-Arab"],"firstnames":["Osama"],"suffixes":[]},{"propositions":[],"lastnames":["Rousse"],"firstnames":["Natacha"],"suffixes":[]},{"propositions":[],"lastnames":["Liu"],"firstnames":["Vincent"],"suffixes":[]},{"propositions":[],"lastnames":["Brandt"],"firstnames":["Caroline"],"suffixes":[]},{"propositions":[],"lastnames":["Foulon"],"firstnames":["Valentin"],"suffixes":[]},{"propositions":[],"lastnames":["Leroy"],"firstnames":["Guillaume"],"suffixes":[]},{"propositions":[],"lastnames":["Schurtz"],"firstnames":["Guillaume"],"suffixes":[]},{"propositions":[],"lastnames":["Jeanpierre"],"firstnames":["Emmanuel"],"suffixes":[]},{"propositions":[],"lastnames":["Duhamel"],"firstnames":["Alain"],"suffixes":[]},{"propositions":[],"lastnames":["Susen"],"firstnames":["Sophie"],"suffixes":[]},{"propositions":[],"lastnames":["Vincentelli"],"firstnames":["André"],"suffixes":[]},{"propositions":[],"lastnames":["Robin"],"firstnames":["Emmanuel"],"suffixes":[]}],"month":"January","year":"2021","note":"Number: 10 Publisher: Multidisciplinary Digital Publishing Institute","keywords":"activated partial thromboplastin time, anti-factor Xa, bleeding, extracorporeal membrane oxygenation, intravenous unfractionated heparin monitoring, thrombotic complications","pages":"2158","bibtex":"@article{moussa_evaluation_2021,\n\ttitle = {Evaluation of {Anti}-{Activated} {Factor} {X} {Activity} and {Activated} {Partial} {Thromboplastin} {Time} {Relations} and {Their} {Association} with {Bleeding} and {Thrombosis} during {Veno}-{Arterial} {ECMO} {Support}: {A} {Retrospective} {Study}},\n\tvolume = {10},\n\tcopyright = {http://creativecommons.org/licenses/by/3.0/},\n\tshorttitle = {Evaluation of {Anti}-{Activated} {Factor} {X} {Activity} and {Activated} {Partial} {Thromboplastin} {Time} {Relations} and {Their} {Association} with {Bleeding} and {Thrombosis} during {Veno}-{Arterial} {ECMO} {Support}},\n\turl = {https://www.mdpi.com/2077-0383/10/10/2158},\n\tdoi = {10.3390/jcm10102158},\n\tabstract = {Background: We aimed to investigate the relationship between anti-activated Factor X (anti-FXa) and activated Partial Thromboplastin Time (aPTT), and its modulation by other haemostasis co-variables during veno-arterial extracorporeal membrane oxygenation (VA-ECMO) support. We further investigated their association with serious bleeding and thrombotic complications. Methods: This retrospective single-center study included 265 adults supported by VA-ECMO for refractory cardiogenic shock from January 2015 to June 2019. The concordance of anti-FXa and aPTT and their correlations were assessed in 1699 paired samples. Their independent associations with serious bleeding or thrombotic complications were also analysed in multivariate analysis. Results: The concordance rate of aPTT with anti-FXa values was 50.7\\%, with 39.3\\% subtherapeutic aPTT values. However, anti-FXa and aPTT remained associated (β = 0.43 (95\\% CI 0.4–0.45) 10−2 IU/mL, p \\< 0.001), with a significant modulation by several biological co-variables. There was no association between anti-FXa nor aPTT values with serious bleeding or with thrombotic complications. Conclusion: During VA-ECMO, although anti-FXa and aPTT were significantly associated, their values were highly discordant with marked sub-therapeutic aPTT values. These results should favour the use of anti-FXa. The effect of biological co-variables and the failure of anti-FXa and aPTT to predict bleeding and thrombotic complications underline the complexity of VA-ECMO-related coagulopathy.},\n\tlanguage = {en},\n\tnumber = {10},\n\turldate = {2021-05-17},\n\tjournal = {Journal of Clinical Medicine},\n\tauthor = {Moussa, Mouhamed Djahoum and Soquet, Jérôme and Lamer, Antoine and Labreuche, Julien and Gantois, Guillaume and Dupont, Annabelle and Abou-Arab, Osama and Rousse, Natacha and Liu, Vincent and Brandt, Caroline and Foulon, Valentin and Leroy, Guillaume and Schurtz, Guillaume and Jeanpierre, Emmanuel and Duhamel, Alain and Susen, Sophie and Vincentelli, André and Robin, Emmanuel},\n\tmonth = jan,\n\tyear = {2021},\n\tnote = {Number: 10\nPublisher: Multidisciplinary Digital Publishing Institute},\n\tkeywords = {activated partial thromboplastin time, anti-factor Xa, bleeding, extracorporeal membrane oxygenation, intravenous unfractionated heparin monitoring, thrombotic complications},\n\tpages = {2158},\n}\n\n","author_short":["Moussa, M. D.","Soquet, J.","Lamer, A.","Labreuche, J.","Gantois, G.","Dupont, A.","Abou-Arab, O.","Rousse, N.","Liu, V.","Brandt, C.","Foulon, V.","Leroy, G.","Schurtz, G.","Jeanpierre, E.","Duhamel, A.","Susen, S.","Vincentelli, A.","Robin, E."],"key":"moussa_evaluation_2021","id":"moussa_evaluation_2021","bibbaseid":"moussa-soquet-lamer-labreuche-gantois-dupont-abouarab-rousse-etal-evaluationofantiactivatedfactorxactivityandactivatedpartialthromboplastintimerelationsandtheirassociationwithbleedingandthrombosisduringvenoarterialecmosupportaretrospectivestudy-2021","role":"author","urls":{"Paper":"https://www.mdpi.com/2077-0383/10/10/2158"},"keyword":["activated partial thromboplastin time","anti-factor Xa","bleeding","extracorporeal membrane oxygenation","intravenous unfractionated heparin monitoring","thrombotic complications"],"metadata":{"authorlinks":{}}},"bibtype":"article","biburl":"https://api.zotero.org/users/1729868/collections/J5D9IHP7/items?key=n4LeME0A45w9AHGzM16k3I3O&format=bibtex&limit=100","dataSources":["9jtzjDGq8xfn9xiA9"],"keywords":["activated partial thromboplastin time","anti-factor xa","bleeding","extracorporeal membrane oxygenation","intravenous unfractionated heparin monitoring","thrombotic complications"],"search_terms":["evaluation","anti","activated","factor","activity","activated","partial","thromboplastin","time","relations","association","bleeding","thrombosis","during","veno","arterial","ecmo","support","retrospective","study","moussa","soquet","lamer","labreuche","gantois","dupont","abou-arab","rousse","liu","brandt","foulon","leroy","schurtz","jeanpierre","duhamel","susen","vincentelli","robin"],"title":"Evaluation of Anti-Activated Factor X Activity and Activated Partial Thromboplastin Time Relations and Their Association with Bleeding and Thrombosis during Veno-Arterial ECMO Support: A Retrospective Study","year":2021}